Richard’s career in the life sciences sector spans 27 years, most recently as a venture capital investor and trusted partner to visionary entrepreneurs. At Omega Funds he was a member of the firm’s investment committee and served as the president of Omega Fund Management LLC; his primary investing focus was in the creation of new drug discovery and development companies. He was also actively involved in the firm’s secondary buyout practice. Representative recent investments he led include Nuvation Bio, Gossamer Bio, Replimune, Morphic Therapeutic, and Paratek Pharmaceuticals. Richard holds degrees from Harvard University and Harvard Business School.